These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24076164)

  • 1. Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
    Spina R; Subbiah R; Markus R; Gunalingam B
    Heart Lung Circ; 2014 Feb; 23(2):171-3. PubMed ID: 24076164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation.
    Wiebe J; Bertog S; Franke J; Wettstein O; Lehn K; Hofmann I; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2014 Apr; 83(5):796-802. PubMed ID: 24327462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left atrial appendage occlusion with the Watchman device in a patient with paroxysmal atrial fibrillation and intolerance of all forms of anticoagulation due to hereditary haemorrhagic telangiectasia.
    Spina R; Gunalingam B
    Intern Med J; 2014 Mar; 44(3):295-7. PubMed ID: 24621286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation.
    Landmesser U; Holmes DR
    Eur Heart J; 2012 Mar; 33(6):698-704. PubMed ID: 22041550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventional treatments for stroke prevention in atrial fibrillation with emphasis upon the WATCHMAN device.
    Möbius-Winkler S; Schuler GC; Sick PB
    Curr Opin Neurol; 2008 Feb; 21(1):64-9. PubMed ID: 18180653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
    Black-Maier E; Piccini JP; Granger CB
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review.
    Baman JR; Mansour M; Heist EK; Huang DT; Biton Y
    Heart Fail Rev; 2018 Mar; 23(2):191-208. PubMed ID: 29453694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial appendage-occluding devices for stroke prevention in patients with nonvalvular atrial fibrillation.
    Yan BP; Kiernan TJ; Gonzales-Cruz I; Lam YY
    Expert Rev Med Devices; 2009 Nov; 6(6):611-20. PubMed ID: 19911873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
    Jones WS; Hellkamp AS; Halperin J; Piccini JP; Breithardt G; Singer DE; Fox KA; Hankey GJ; Mahaffey KW; Califf RM; Patel MR
    Eur Heart J; 2014 Jan; 35(4):242-9. PubMed ID: 24302273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.
    Gangireddy SR; Halperin JL; Fuster V; Reddy VY
    Eur Heart J; 2012 Nov; 33(21):2700-8. PubMed ID: 23008509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial.
    Belgaid DR; Khan Z; Zaidi M; Hobbs A
    Int J Cardiol; 2016 Sep; 219():177-9. PubMed ID: 27343417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation: a percutaneous-device delivery approach.
    Lerakis S; Synetos A
    Future Cardiol; 2007 Sep; 3(5):507-9. PubMed ID: 19804304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
    Hankey GJ; Patel MR; Stevens SR; Becker RC; Breithardt G; Carolei A; Diener HC; Donnan GA; Halperin JL; Mahaffey KW; Mas JL; Massaro A; Norrving B; Nessel CC; Paolini JF; Roine RO; Singer DE; Wong L; Califf RM; Fox KA; Hacke W;
    Lancet Neurol; 2012 Apr; 11(4):315-22. PubMed ID: 22402056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
    Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
    Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpharmacologic approaches to stroke prevention in atrial fibrillation.
    Whitlock RP; Hanif H; Danter M
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S79-86. PubMed ID: 23790602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety of the WATCHMAN Device in LAA Occlusion in Patients with Non-Valvular Atrial Fibrillation Contraindicated to Oral Anticoagulation: A Focused Review.
    Majule DN; Jing C; Rutahoile WM; Shonyela FS
    Ann Thorac Cardiovasc Surg; 2018 Dec; 24(6):271-278. PubMed ID: 29962388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.